Cagrilintide vs Melanotan II
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Melanotan II |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. |
| Best For |
What They Have in Common
Both Cagrilintide and Melanotan II are commonly used for: